Alzheimer’s sleep loss traces back to the brain’s own immune cells turning on neurons

For decades, the disrupted sleep that torments many people with Alzheimer’s disease was treated as a byproduct of the sticky amyloid plaques that accumulate in the aging brain. A new study argues the real culprit is somewhere else entirely: the brain’s own immune cells. Researchers report that overactive microglia, not the plaques, drive the sleep loss, and that quieting those cells restored more than two hours of rest a night in laboratory mice without removing a single plaque.

The finding matters because sleep disruption is one of the most disabling and least treatable features of the disease. It exhausts patients, wears down the family members who care for them, and may feed back into the underlying decline. If the mechanism runs through immune cells rather than plaques, it points toward a different set of possible treatments.

What microglia do in the brain

Microglia are the resident immune cells of the central nervous system, acting as the brain’s cleanup and defense crew. They patrol for damage, clear debris and prune connections between neurons. In a healthy brain that housekeeping is essential, but in Alzheimer’s the cells can shift into a chronically activated, inflammatory state. The University of Kentucky team behind the work set out to test whether that overactivity was doing more than mopping up plaques, and whether it was directly interfering with the circuits that govern sleep.

The study was led by Shannon L. Macauley and published in the journal Alzheimer’s & Dementia. The core idea overturns a long-standing assumption: that sleep problems in Alzheimer’s are downstream of amyloid buildup and would ease only if the plaques were cleared. Instead, the researchers proposed that inflamed microglia were acting on neurons in a way that kept the brain from settling into rest.

Silencing the cells restored two hours of sleep

To test the theory, the team used a drug to temporarily silence the microglia in mice engineered to develop Alzheimer’s-like pathology. According to the reported results, the treatment shut down roughly 87 percent of the immune cells, and the animals gained more than two hours of restorative sleep per night. Critically, the plaques stayed exactly where they were. The improvement came without clearing any amyloid, which is the point the researchers stress most: rest returned even though the deposits blamed for decades remained in place.

That separation matters for how the field thinks about the disease. Much of Alzheimer’s drug development has aimed at removing or blocking amyloid, on the theory that plaques cause the cascade of symptoms. The new results suggest at least one symptom, and a punishing one, can be addressed on a separate track by calming the immune response instead of attacking the deposits.

A symptom that breaks patients and caregivers

Sleep disruption is not a minor complaint in Alzheimer’s. Estimates cited alongside the study indicate that somewhere between a quarter and nearly half of patients experience significant, clinically disabling sleep problems. As coverage of the research notes, it ranks among the disease’s most debilitating features and is one of the leading reasons caregivers report exhaustion and burnout. Nighttime wandering, agitation and fragmented rest often push families toward the difficult decision to move a loved one into full-time care.

Because the burden falls so heavily on households, a treatment that restored even a couple of hours of reliable sleep could change daily life well beyond the patient. Better rest may also carry biological benefits, since sleep is when the brain performs some of its own maintenance, though the study focused on the mechanism rather than long-term outcomes.

Repurposing existing drugs to reset the cells

The mice were treated with an experimental approach, but the researchers are already looking at medications that are widely available and well understood. Macauley’s laboratory is exploring whether existing drugs can reset the way microglia use fuel and dial back their overactivity. Two candidates named by the team are metformin, a common diabetes medication, and stiripentol, an antiseizure drug. Both already have safety records in humans, which could shorten the path from laboratory finding to clinical testing if the effect holds up.

Repurposing approved drugs is an attractive route precisely because their side-effect profiles and dosing are established, sparing researchers the years of early safety work a brand-new compound requires. Whether either drug can reproduce in people the sleep restoration seen in mice remains an open question that will need dedicated trials to answer.

What still has to be proven

The results come from a mouse model, and the history of Alzheimer’s research is full of promising animal findings that did not translate to patients. Human brains are more complex, the disease unfolds over years, and temporarily silencing immune cells carries its own risks that would have to be weighed carefully. The study does not claim to slow the disease or reverse cognitive decline; its contribution is to relocate the source of one major symptom.

Still, the shift in thinking is notable. By pointing at inflamed microglia rather than amyloid plaques, the work broadens the target list for a disease that has frustrated drug developers for a generation, and it suggests that relief for one of Alzheimer’s cruelest symptoms may not have to wait for a cure.

This article was researched and drafted with the assistance of AI and reviewed before publication.

More from Morning Overview